OncoSec Medical Inc (NASDAQ:ONCS) shares traded down 5.7% on Tuesday . The stock traded as low as $1.75 and last traded at $1.83. 1,263,990 shares changed hands during trading, an increase of 75% from the average session volume of 722,009 shares. The stock had previously closed at $1.94.

Several research analysts have recently weighed in on the stock. HC Wainwright set a $6.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a research report on Friday, December 15th. Maxim Group set a $5.00 price target on shares of OncoSec Medical and gave the company a “buy” rating in a research report on Thursday, December 14th. Finally, ValuEngine cut shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. OncoSec Medical presently has a consensus rating of “Buy” and a consensus target price of $5.33.

The firm has a market cap of $65.00, a price-to-earnings ratio of -1.78 and a beta of 3.27.

OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.05). equities analysts anticipate that OncoSec Medical Inc will post -0.86 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/01/16/oncosec-medical-oncs-stock-price-down-5-7.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.